Abstract
Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
| Original language | English |
|---|---|
| Journal | International Journal of Clinical Oncology |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Cytotoxic drug
- Immune checkpoint inhibitor
- Squamous cell carcinoma of the lung
ASJC Scopus subject areas
- Surgery
- Hematology
- Oncology
Cite this
Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. / Senoo, Satoru; Ninomiya, Kiichiro; Hotta, Katsuyuki; Kiura, Katsuyuki.
In: International Journal of Clinical Oncology, 01.01.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan
AU - Senoo, Satoru
AU - Ninomiya, Kiichiro
AU - Hotta, Katsuyuki
AU - Kiura, Katsuyuki
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
AB - Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
KW - Cytotoxic drug
KW - Immune checkpoint inhibitor
KW - Squamous cell carcinoma of the lung
UR - http://www.scopus.com/inward/record.url?scp=85062685719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062685719&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01424-y
DO - 10.1007/s10147-019-01424-y
M3 - Review article
C2 - 30847617
AN - SCOPUS:85062685719
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
ER -